ADS-TEC Energy (NASDAQ:ADSE) Stock, Quote.Headers.trade-ideas

ADS-TEC Energy

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADSE

BCDA

BNRG

DELL

DLTH

EKSO

ESTC

FCUV

LGMK

LUCY

LUNR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MRVL

PALT

ULTA

VTAK

XRTX

Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Wall Street US stocks

Short Ideas

AMSC

Top 3 Industrials Stocks That Are Ticking Portfolio Bombs

Penny Stocks

Small Cap

Intraday Update

ACMR

BYND

CTKB

EYPT

IRTC

LYEL

NYCB

OMER

PLTK

RIVN

RVNC

SABR

SANA

SAVE

TSLA

VSCO

U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.

Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday

ADS-TEC Energy PLC

New York City is intensifying its efforts to curb illegal cannabis sales as a City Council committee meets today, Sept. 17, to assess the impact of Mayor Eric Adams&#8216; <a href="https://www.benzinga.com/markets/cannabis/24/08/40615428/4-tons-of-seized-marijuana-burnt-to-a-crisp-by-nyc-mayor-adams-top-cop-sheriff-join-the-cannabis">&#8220;Operation Padlock to Protect.&#8221;</a>
Launched in May of 2024, the initiative grants law enforcement the authority to inspect smoke shops and cannabis retailers, padlocking any stores found selling illegal cannabis.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40383430/ny-city-council-to-hochul-stop-cannabis-buffer-zone-loosening-because-it-encourages-illegal-sale">NY City Council To Hochul: Stop Cannabis Buffer Zone Loosening Because &#8216;It Encourages Illegal Sales&#8217;</a>
Authorities have shuttered 210 stores in the Bronx alone under the program, including Family Deli on East Tremont Avenue, where they confiscated over 170 pounds of cannabis, News12Brooklyn<a href="https://brooklyn.news12.com/has-operation-padlock-to-protect-been-effective"> reported.</a>
Mayor Adams recently confirmed that by the end of August, officials had sealed 1,000 illegal <a href="https://www.benzinga.com/markets/cannabis/24/07/40085217/new-york-shuts-down-over-1-000-illegal-cannabis-stores-boosting-legal-sales-by-72">cannabis shops citywide.</a>
<h3 class="wp-block-heading">Operation Padlock&#8217;s Impact On Legal Cannabis Businesses</h3>
Operation Padlock has been a game-changer for licensed cannabis retailers in New York. Many shop owners reported a substantial increase in sales after the crackdown began. 
According to statements made to Governor Kathy Hochul&#8217;s office, legal cannabis businesses experienced a 72% rise in sales within three months of the operation&#8217;s launch.
Licensed cannabis operators have long struggled to compete with unlicensed retailers that have been able to undercut prices. By shutting down illicit businesses, the city is helping to level the playing field for those following the rules.
<h3 class="wp-block-heading">Next Steps For Operation Padlock</h3>
The City Council will review the overall effectiveness of Operation Padlock, focusing on how authorities store and dispose of seized products. As enforcement continues, the city hopes to prevent illegal businesses from reopening under different names or in new locations.
City officials encourage New Yorkers to report concerns about illegal cannabis sales to the 311 hotline. Still, some question the legality of the proceedings.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40496042/new-yorks-legal-cannabis-market-surpasses-500m-after-crackdown-on-illegal-shops">New York&#8217;s Legal Cannabis Market Surpasses $500M After Crackdown On Illegal Shops</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39322748/unlicensed-cannabis-sellers-fight-back-suing-nyc-for-unconstitutional-crackdowns">Unlicensed Cannabis Sellers Fight Back, Suing NYC For &#8216;Unconstitutional&#8217; Crackdowns</a></li>
</ul>

Cannabis

Is Mayor Adams' Crackdown On Illegal Cannabis Working? NYC Council Weighs In After 1,000+ Store Closures

Whether the Federal Reserve will implement a 25-basis-point reduction or a 50-basis-point cut, is top of mind <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40908202/10-etfs-investors-secretly-bought-before-the-feds-make-or-break-interest-rate-cal">ahead of Wednesday&#8217;s meeting</a>.
But there&#8217;s an "even bigger question" to answer, Thomas Hayes of Great Hill Capital tells Benzinga.
What will Japan's central bank decide at its meeting on Friday? Recall how Japan's <a href="https://www.benzinga.com/markets/asia/24/09/40692633/japanese-yen-rallies-on-bank-of-japans-rate-hike-pledge-us-manufacturing-activity-contraction">rate hikes created volatility</a>, particularly in tech stocks.
&#8220;Fed should have cut [rates] in August,&#8221; Hayes says. Instead, Japan&#8217;s central bank hiked and the Fed didn't. As a result, &#8220;it created a liquidity mismatch that caused an abrupt selloff&#8221; in <a href="https://www.benzinga.com/topic/magnificent-seven">the Magnificent Seven stocks</a>.
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40907441/gold-etfs-poised-for-liftoff-can-the-feds-rate-cut-propel-prices-to-new-heights">Gold ETFs Poised For Liftoff: Can The Fed&#8217;s Rate Cut Propel Prices To New Heights?</a>
If the Bank of Japan (BoJ) meets Friday and hikes again while the Fed only cuts 25 basis points, more turbulence could arise, Hayes predicts. Things should be alright if the Fed cuts 50 basis points and the BoJ hikes 25 basis points, he says. Likewise, if the BoJ keeps rates unchanged and the Fed cuts 25 basis points. The Fed's Decision: Of the last three 50 basis-point cuts, March 2020 &#8220;worked great,&#8221; Hayes recalls. The cuts from September 2007 and January 2001 each has a &#8220;bad outcome.&#8221;
Fed Fund Futures suggest a 65% chance of a 50 basis-points cut, though Hayes isn't sure. 
A cut that size could suggest the Fed is falling behind. It might also give the appearance of political motivation, which the Fed will most likely try to avoid. With the effective federal funds rate (EFFR) at 5.33%, more than 230 basis points above inflation, Hayes believes monetary policy is already too restrictive.
Hayes expects the Fed will go with a 25 basis points cut paired with dovish commentary, suggesting further cuts in November and December. While the market is pricing in 100-125 basis points of cuts by year-end, Hayes is in the 75-100 basis points of reductions camp.
Hayes also points to stronger-than-expected growth, with Q3 GDPNow estimates at 2.5% and 15% earnings per share (EPS) growth forecast for 2024. "Hard to have a recession with GDP growing over 2%," Hayes said.&nbsp;
Hayes is not repositioning ahead of the rate cuts. However, other major funds made significant moves in the second quarter ahead of the rate-cut cycle. According to <a href="https://hedgefollow.com/Largest-Hedge-Fund-Buys.php">HedgeFollow</a>:
<ul>
<li>Berkshire Hathaway <a href="https://www.benzinga.com/markets/24/08/40303410/warren-buffett-declares-shift-selling-apple-stock-to-invest-in-this-magnificent-megacap-heres-why">sold</a> more Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares</li>
<li>State Street <a href="https://www.benzinga.com/news/24/06/39368302/state-street-technology-etf-to-put-nvidia-before-apple-in-revamp">bought</a> Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares</li>
<li>Coatue <a href="https://drupal-cloudfront.benzinga.com/trading-ideas/long-ideas/24/08/40423475/legendary-hedge-fund-coatue-buys-nvidia-stock-hand-over-fist-ups-stake-nearly-10x">picked up</a> Nvidia and Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>Two Sigma bought CME Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) shares.</li>
</ul>
Now Read: <a href="https://www.benzinga.com/markets/equities/24/09/40909187/s-p-500-briefly-hits-record-high-just-ahead-of-fed-rate-cut-extends-7-day-winning-streak-tuesday">S&amp;P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak</a>
Image: Shutterstock

Global

General

AAPL

NVDA

As Fed Gears Up For Cuts, One Hedge Funder Is Focused On A Bigger Catalyst: Japan's Central Bank

Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares are blasting higher in extended trading Tuesday after the company announced it was awarded a NASA contract for communication and navigation services in the near space region, which extends from <a href="https://www.benzinga.com/pressreleases/24/09/g40909157/nasa-awards-intuitive-machines-near-space-network-contract-with-a-maximum-potential-value-of-4-82-">Earth&#8217;s surface to beyond the Moon.</a>
The Details: The contract is a new firm-fixed-price, multiple award, indefinite-delivery/indefinite-quantity (IDIQ) task order contract with a base period of five years and an additional five-year option period, with a maximum potential value of $4.82 billion. 
The incrementally funded base ordering period begins Oct. 1, 2024 and goes through Sept. 30, 2029, with the option period potentially extending the contract through Sept. 30, 2034.
Intuitive Machines highlighted the debut of its lunar satellite constellation in connection with the contract.&nbsp; The company said the satellite constellation will deploy lunar relay satellites and provide communication and navigation services that play an essential role in NASA&#8217;s Artemis campaign to establish a long-term presence on the Moon.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40888466/what-happened-with-microstrategy-stock-today">What Happened With MicroStrategy Stock Today?</a>
&#8220;This contract marks an inflection point in Intuitive Machines&#8217; leadership in space communications and navigation,&#8221; said Intuitive Machines CEO Steve Altemus. &#8220;We&#8217;re pleased to partner with NASA, as one team, to support the Artemis campaign and endeavors to expand the lunar economy.&#8221;
LUNR Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Intuitive Machines shares are up 37.04% after-hours at $7.40 at the time of publication Tuesday. 
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40887805/whats-going-on-with-tupperware-brands-stock">What&#8217;s Going On With Tupperware Brands Stock?</a></li>
</ul>
Photo: Courtesy of Intuitive Machines, Inc.

After-Hours Center

Why Intuitive Machines' Stock Is Blasting Off In Extended Trading

Vehicle 2 will be used for commercial operations going forward.&nbsp;Completion of this testing is intended to certify the vehicle for water depths exceeding 2000 meters.
Development and testing of additional Aquanaut Mark 2 capabilities will continue with Vehicle 1, currently undergoing a deepwater electronics upgrade in&nbsp;Houston. Open water testing is expected to begin at&nbsp;Florida Atlantic University&nbsp;(FAU) later this year.

KITT

Nauticus Robotics Commences Its Second Round Of Qualification Testing Of Its Flagship Underwater Vehicle, Aquanaut Mark 2, In The Gulf Of Mexico

ENLC intends to fund the redemption and associated costs with borrowings under its revolving credit facility.

ENLC

EnLink Midstream Reports Redemption Of Its 6.000% Series C Fixed-to-floating Rate Cumulative Redeemable Perpetual Preferred Units

Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) closed lower Tuesday after the company outlined its long-term growth strategy at <a href="https://www.benzinga.com/pressreleases/24/09/b40908084/electronic-arts-outlines-long-term-growth-strategy-at-investor-day">its Investor Day event. </a>
The Details: EA shared an in-depth look at the initiatives and experiences driving its strategic pillars to accelerate growth and outlined how AI drives efficiency, expansion and transformation at EA. The company said it is on track toward the high end of the net bookings guidance for the second quarter and fiscal year. 
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40888466/what-happened-with-microstrategy-stock-today">What Happened With MicroStrategy Stock Today?</a>
EA said it expects sustained growth in EA SPORTS and outlined plans for new business opportunities beyond gaming, including the EA SPORTS App. It described the EA SPORTS App as socially driven with sports content, live sports data, interactivity and gaming centered on global football. 
"We are excited to unveil an in-depth look inside the growing scale and scope of our IP portfolio, as we accelerate engagement and social connection in and around our biggest franchises,&#8221; said Andrew Wilson, CEO of EA.
&#8220;We are also introducing new experiences and leveraging innovative technology to serve our global communities and attract new audiences, as we continue to transform our business and shape the future of entertainment,&#8221; Wilson added.&nbsp;
EA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Electronic Arts shares ended Tuesday's session down 2.68% at $142.59.&nbsp;&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40887805/whats-going-on-with-tupperware-brands-stock">What&#8217;s Going On With Tupperware Brands Stock?</a></li>
</ul>
Photo: Shutterstock

Gaming

What Happened With Electronic Arts Stock Today?

ALCO

Alico Amends Its Credit Agreement With MetLife; Increases Borrowing Capacity Under Revolving Line Of Credit From $25M To $95M, Extends Maturity Date To May 1, 2034

The company announced the pricing of a public offering of an aggregate of 5.55 million common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5.55 million common shares and Series A-2 common warrants to purchase up to 5.55 million&nbsp;common shares, at a combined public offering price of&nbsp;$0.72&nbsp;per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant.&nbsp;

Offerings

CYTO

Altamira Therapeutics Reports Pricing Of Up To $12M Public Offering; $4M Upfront With Up To Additional $8M Of Aggregate Gross Proceeds Upon Exercise Of Milestone-linked Warrants

Now that final clearance has been received from regulators, Alaska Airlines can close the transaction and shift focus to obtaining a single operating certificate from the Federal Aviation Administration (FAA).&nbsp;
When the combination was announced, it was shared that Hawaiian Airlines President and CEO&nbsp;Peter Ingram&nbsp;would step down from his role following the transaction close. Current Alaska Airlines regional president of Hawai&#39;i/Pacific,&nbsp;Joe Sprague, will be named chief executive officer of Hawaiian Airlines.
In this role, Sprague will be responsible for leading all aspects of Hawaiian Airlines&#39; operations until the FAA grants&nbsp;Alaska&nbsp;a single operating certificate.

Management

Alaska Air Reveals Interim Honolulu Leadership Team Will Lead The Hawaiian Airlines Operation

Technology giant Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is teaming up with investment company BlackRock and several other partners on a new $30 billion investment fund to target the growing <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence sector.</a>
What Happened: The new investment, which adds to Microsoft's <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/01/30527688/microsoft-ramps-efforts-to-build-ai-supercomputer-with-chatgpt-ahead-of-q2-earnings">growing bets on the AI space</a>, includes the participation of BlackRock, Global Infrastructure Partners and MGX.
The investment fund, called Global AI Infrastructure Investment Partnership (GAIIP), will invest in data centers and supporting power infrastructure. The fund will make investments "in new and expanded data centers to meet growing demand for computing power."
The fund partners <a href="https://www.businesswire.com/news/home/20240917764857/en/BlackRock-Global-Infrastructure-Partners-Microsoft-and-MGX-Launch-New-AI-Partnership-to-Invest-in-Data-Centers-and-Supporting-Power-Infrastructure">said </a>the investments will help the U.S. fuel "AI innovation and economic growth."
Investments will also be made in U.S. partner countries.
The announcement said NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) will support the newly formed GAIIP by offering "its expertise in AI data centers and AI factories to benefit the AI ecosystem."
"NVIDIA will use its expertise as a full stack computing platform to support GAIIP and its portfolio companies on the design and integration of AI factories to propel industry innovation," Nvidia CEO Jensen Huang said.
While the fund initially seeks to invest $30 billion from investors, asset owners and corporations, the total investment could hit $100 billion when debt financing is included.
"Mobilizing private capital to build AI infrastructure like data centers and power will unlock a multi-trillion-dollar long-term investment opportunity," BlackRock CEO Larry Fink said. "Data centers are the bedrock of the digital economy."
Microsoft CEO Satya Nadella said the investment shows the company's commitment to advancing AI.
"The Global AI Infrastructure Investment Partnership will help us deliver on this vision, as we bring together financial and industry leaders to build the infrastructure of the future and power it in a sustainable way," Nadella said.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/07/40051051/microsoft-q4-earnings-highlights-revenue-beat-eps-beat-cloud-revenue-up-21-yoy-ensuring-we-lead-the">Microsoft Q4 Earnings Highlights: Revenue Beat, EPS Beat, Cloud Revenue Up 21% YoY, &#8216;Ensuring We Lead The AI Era&#8217;</a>
Why It's Important: The new investment group will seek to improve the competitiveness of the U.S. in the AI space along with meeting the increased need for energy infrastructure.
The partnership brings in companies involved in the field of AI or experienced in securing investments from outside parties, which could make a winning combination.
With the growing demand for artificial intelligence capabilities, investments continue to flow to the sector. The new investment group could attract strong interest given the notable names involved.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36301925/emerging-ai-trends-in-2024-blackrock-sees-shift-beyond-semiconductors-cloud-to-mode">Emerging AI Trends In 2024: BlackRock Sees Shift Beyond Semiconductors, Cloud To Model Infrastructure</a></li>
</ul>

Financing

Tech

MSFT

BlackRock, Microsoft, Others Team Up For $30B Artificial Intelligence Fund: Help US Fuel 'AI Innovation And Economic Growth'

Stifel analyst Stephen Gengaro maintains DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) with a Buy and lowers the price target from $19 to $17.

Price Target

Analyst Ratings

BOOM

Stifel Maintains Buy on DMC Glb, Lowers Price Target to $17

IPOs

YHN Acquisition I Limited Prices IPO Of 6M Units At $10.00 Per Unit

&quot;Although this situation will affect revenues in the&nbsp;fourth quarter&nbsp;of 2024, we remain on track to deliver a strong Adjusted EBITDA in the current fiscal year and will be providing more details as part of the release of our&nbsp;third quarter&nbsp;results in October,&quot; the company said.

Guidance

THTX

Theratechnologies Expects EGRIFTA SV Supply Disruption To Affect Revenues In Q4 Of 2024

Truist Securities analyst Jasper Bibb maintains Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) with a Buy and raises the price target from $212.5 to $225.

CTAS

Truist Securities Maintains Buy on Cintas, Raises Price Target to $225

The Company plans to implement measures to carefully manage the inventory levels of&nbsp;EGRIFTA SV&nbsp;to meet patient demand until early January 2025, and estimates that these measures will result in a shortfall of approximately $1.6 million in revenue from&nbsp;EGRIFTA SV&nbsp;for its fiscal year 2024.

Theratechnologies Reveals Risk Of Temporary Supply Disruption For EGRIFTA SV In Early 2025 Caused By An Unexpected Voluntary Shutdown Of Contract Manufacturer's Facility Following FDA Inspection

Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and raises the price target from $14 to $15.

CAPR

Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $15

<ul>
<li>High-single-digits to double-digits Annual Contract Value&nbsp;(&quot;ACV&quot;) growth</li>
<li>ACV margin&nbsp;of&nbsp;45-47%</li>
<li>Mid-teens free cash flow3&nbsp;growth</li>
</ul>

AZPN

Aspen Technology Reaffirms Outlook For FY25, Provides Multi-year Financial Outlook As Part Of Its 2024 Investor Day

Across the recent three months, 9 analysts have shared their insights on Inari Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Inari Medical, revealing an average target of $58.78, a high estimate of $71.00, and a low estimate of $47.00. Highlighting a 2.31% decrease, the current average has fallen from the previous average price target of $60.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1726606859_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Inari Medical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inari Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inari Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Inari Medical's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NARI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Inari Medical analyst ratings.</a>
<h2>About Inari Medical</h2>
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
<h3>Inari Medical: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Inari Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 22.53%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Inari Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -21.5%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Inari Medical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.7%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Inari Medical's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NARI

Expert Outlook: Inari Medical Through The Eyes Of 9 Analysts

Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Editas Medicine and provided 12-month price targets. The average target is $11.75, accompanied by a high estimate of $15.00 and a low estimate of $7.00. Experiencing a 16.07% decline, the current average is now lower than the previous average price target of $14.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726606841_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Editas Medicine by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soumit Roy</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Editas Medicine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Editas Medicine compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Editas Medicine's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Editas Medicine's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EDIT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Editas Medicine analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Editas Medicine</h2>
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
<h3>Understanding the Numbers: Editas Medicine's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Editas Medicine's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -82.23%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Editas Medicine's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13178.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -25.69%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -16.39%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Editas Medicine's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EDIT

Where Editas Medicine Stands With Analysts

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $208.62, a high estimate of $265.00, and a low estimate of $150.00. A decline of 16.86% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1726606824_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Penumbra. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$263.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$187.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$176.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$178.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$232.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$265.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Penumbra's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Penumbra analyst ratings.</a>
<h2>About Penumbra</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
<h3>Breaking Down Penumbra's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Penumbra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.49% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -20.11%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Penumbra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -5.09%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.87%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.2, Penumbra adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Penumbra

ADS-TEC Energy reports FY results

ADS-TEC Energy PLC (ADSE) Q4 2023 Earnings Call Transcript

ADS-TEC Energy signs service agreement with Porsche

In a report released today, Matt Summerville from D.A. Davidson maintained a Hold rating on ADS-TEC Energy (ADSE – Research Report). The company's ...

D.A. Davidson Reaffirms Their Hold Rating on ADS-TEC Energy (ADSE)

ADS-TEC Energy (ADSE) has released an update. ADS-TEC Energy has issued an Amended and Restated Secured Promissory Note, renewing and substituting ...

ADS-TEC Energy Announces New Financing Terms

ADS-TEC Energy (ADSE) has released an update. ADS-TEC Energy plc has announced its Annual General Meeting (AGM) for September 23, 2024, where share...

ADS-TEC Energy Announces Upcoming AGM

ADS-TEC Energy reports 1H results

ADS-TEC Energy PLC (ADSE) Q2 2024 Earnings Call Transcript

ADS-TEC Energy (ADSE) has released an update. ADS-TEC Energy has reported a significant year-over-year revenue growth of 107% in the first half of ...

ADS-TEC Energy Achieves Strong H1 2024 Growth

ADS-TEC Energy: Robust Growth, Much Potential Ahead

ADSEW

BLNK

EOSE

EOSEW

POAHF

POAHY

Press Releases

ADS-TEC Energy (ADSE) Reports Full-Year Fiscal 2023 Results and Provides Business Update

Green Product Award Winner 2024: ChargePost from ADS-TEC Energy Recognized as a Sustainable, Future-Proof Product

ADS-TEC Energy Delivers First Quarter 2024 Trading Update

Award-winning once again: ChargePost from ADS-TEC Energy honored with German Innovation Award 2024

ADS-TEC Energy and Porsche Sign Worldwide Service Agreement

ADS-TEC Energy Launches New Product Features at Power2Drive Europe

ADS-TEC Energy and Caverion Extend Their Partnership to Denmark and Sweden

ADS-TEC Energy's ChargePost wins Red Dot Design Award for sustainability, innovation and design

ADS-TEC Energy (ADSE) to Host Business Update Call on September 12th Following the Release of Half-Year 2024 Results

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

ADS-TEC Energy

ADS-TEC Energy (ADSE) Forecast

ADS-TEC Energy (NASDAQ:ADSE) Stock, Quote.Headers.trade-ideas